No re'gime of therapv which will cure acute leukaemia is yet available. The use of blood transfusions, antibiotics, steroid hormones, the purine or folic acid antagonists will, in some cases, cause temporary improvement. A few patients treated by these agents may be restored for short periods to almost normal health. These measures, however, have been aptly described by Dameshek (1957) Our cases were classified as-monoblastic 21, myeloblastic 10, lymphoblastic 10, and in 9 cases it was considered that the cells showed no differentiation and these were designated as stem cell or blast cell leukaemia.
really good agents become available, the present re'gimes would be rapidly discarded. Until such an event occurs, it is pertinent to examine the therapies at present available and attempt to assess the optimum way in which they can be used.
The difficulties in attempting to assess the relative merits of the various therapeutic re'gimes, as reported from different centres, have been repeatedly emphasised (Wintrobe, 1957 Hayhoe, 1960. In reported series, the selection of patients, the morphological types of disease, the efficiency of what Farber (1957) (1935) we found these methods added little of value.
Our cases were classified as-monoblastic 21, myeloblastic 10, lymphoblastic 10, and in 9 cases it was considered that the cells showed no differentiation and these were designated as stem cell or blast cell leukaemia.
In assessing the results of therapy in our patients we have classified the response into three grades-complete, partial All patients in the present series were given blood transfusions and antibiotics as indicated. It has been claimed by Dreyfus (1948) , Bessis and Dausset (1950) , and Hayboe and Whitby (1955) that remissions may be induced in a significant number of adult patients with acute leukaemia by the use of blood transfusions alone. We, however, have not attempted to allow for benefit following nonspecific tberapy, and in assessing our results have assumed that the benefits of such therapy, if any, were equal in both main groups.
Therapeutic Regimes
The 50 patients in the present series fall into two distinct groups-(a) those given 6-Mercaptopurine alone, and (b) those given steroids in combination with 6-Mereaptopurine.
6-Mercaptopurine
The drug 6-Mercaptopurine, which blocks the metabolism of purine by inhibiting the formation of nucleic acid, was first subjected to clinical trial by Burchenal, Murpby, Ellison, Sykes, Tan, Leon, Karnofsky, Craver, Dargeon and Rboads (1953) and by Hall, Richards, Willet and Feichtmeir (1954) . These studies suggested that the drug was of value in the treatment of chronic granulocytic and acute leukaemia but not in other malignant diseases ; these findings have since been confirmed by many authors.
The dose schedule which we employed was 2-5 mg. per kilo body weight daily to a total dose of 6-8 g. over a period of 4-6 weeks. Evidence of a haematologica-I response usually appeared after therapy had been given for 2 weeks, the maximum benefit being evident after 4 weeks. It was found that the degree of clinical improvement paralleled the haematological remission.
In all our cases the action of the drug was confined to the haemopoietic system. In the patients who responded leucopaenia occurred which was mainly due to elimination of the primitive cells from the peripheral blood. In no case was it considered that thromboyetopaenia or anaemia was caused solely by a toxic action of the drug on either megakaryocytes or red cell precursors.
Fourteen cases have been treated with 6-Mercaptopurine alone ( In Table IV (Zuelzer, 1949 ; Koler, Seaman and Osgood, 1956 
DISCITSSION
It is now generally agreed that 6-Mercaptopurine and steroids are the drugs of most value in the manactement of acute leukaemia in the adult but the optimum wav in which these agents should be used is as yet not clearly established. The present work attempts to assess the efficiency of initial therapy with 6-Mercaptopurine alone as compared with 6-Mercaptopurine and steroids combined. These regimes may be judged by comparing the relative numbers of patients achieving some worth while response and the average survival of patients treated by each method. One difference between the two re'gimes which we have noted and which does not become apparent from studying the data we have presented, is the pattern of response. In patients given 6-Mereaptopurine, the response occurred only after some 2 to 3 weeks therapy, whereas amongst those given combined therapy the large majority of responses were evident within 10 days. This difference in the pattern of response which has previously been noted (Hayhoe, 1960) would suggest that steroids may act not only as a cytotoxic agent but also may have a direct stimulatory effect on surviving normal marrow elements (Dameshek and Gunz, 1958 
